Dermal scarification versus intramuscular diclofenac sodium injection for the treatment of renal colic: a prospective randomized clinical trial.

The aim of the study is to determine whether dermal scarification is equally effective for treating acute renal colic compared to diclofenac sodium intramuscular therapy. A prospective, randomized controlled study was conducted with methodologic rigor based on CONSORT criteria. A total of 291 patients, aged ≥ 18 years, suffering from acute renal colic were included in this trial and randomly assigned in two groups.

Treatment of male genital lichen sclerosus with clobetasol propionate and maintenance with either methylprednisolone aceponate or tacrolimus: a retrospective study.

Objective: To assess the efficacy of clobetasol propionate 0.05% cream in male patients suffering from genital lichen sclerosus (GLS), as well as the efficacy of methylprednisolone aceponate 0.1% cream and tacrolimus 0.

A therapeutic approach for female, relapsing genital lichen sclerosus: a single-center study.

Objective: To assess the efficacy of methylprednisolone aceponate 0.1% (MPA 0.1%) in female genital lichen sclerosus (GLS) and efficacy of MPA, tacrolimus or emollient for prevention of flares.

Preclinical compounds for the treatment of overactive bladder.

Background: Overactive bladder is a prevalent and bothersome condition. Existing pharmacotherapy with antimuscarinics improves symptoms and quality of life but there are certain limitations in efficacy and tolerability.

Objective: To review novel, recently patented compounds for the treatment of overactive bladder.

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.

Sildenafil was the first orally administered phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. Its successful introduction into clinical practice was soon followed by the launch of two other phosphodiesterase-5 inhibitors: vardenafil and tadalafil. The plethora of choices made the question "which PDE-5 inhibitor?" relevant for patients and clinicians.